Covid-19

Amid the constant headlines of case numbers, vaccine efficacy, mask mandates, and other Covid-19 news, Yulan Egan steps back and asks an important question: What factors really matter when it comes to understanding the delta variant surge?

From the United Kingdom, to Canada, to the United States, health care leaders are starting the challenging work of not only improving outcomes for the most vulnerable populations but also ensuring their leadership teams represent those communities largely excluded from the boardroom.

Covid-19 has exacerbated the health inequities of many communities across the nation, and Dallas County is no exception. Fred Cerise, CEO of Parkland, and Steve Miff, president and CEO of Parkland's Center for Clinical Innovation, joined the Radio Advisory podcast to discuss why and how they are addressing inequities in Covid-19 vaccinations.

Health systems have had no shortage of challenges over the last year—and now, they face the added challenge of an increasingly complex vaccine rollout, one that requires ongoing coordination with a wide variety of external stakeholders, from public health agencies, to pharmaceutical companies, to tech companies, and more.

We talked to dozens of clinical executives in the past month about how they're staffing for Covid-19—here's what we learned.

Johnson & Johnson and Novavax separately released preliminary clinical trial data on their Covid-19 vaccine candidates. Here's what the data shows—and what it could mean for America's coronavirus epidemic, according to experts.

FDA has just authorized a coronavirus vaccine created by Pfizer and BioNTech, and tens of millions of doses will begin rolling out within days. We now know enough to answer some of our lingering questions—and to draw conclusions about the effectiveness both of FDA's review process and of the vaccine itself.

Moderna’s vaccine was also authorized for emergency use in December 2020. Brandi Greenberg again answered our 8 biggest questions about the safety and efficacy of this vaccine, and also discussed how it compares to the Pfizer vaccine.

We spoke with Moderna’s CEO about how his company designed a coronavirus vaccine in just two days, how his team collaborated with Operation Warp Speed, and his plan to develop vaccines against potentially deadly viruses before they strike humans.

We spoke with the CEO of Johnson and Johnson about how his company developed a vaccine in "months rather than years," why he's more interested in cultivating a "sustainable innovation culture" than ironing out a 30-year strategic plan, the trend he thinks will be "ubiquitous across health care going forward," and more.